Claims for Patent: 10,449,176

Summary for Patent: 10,449,176

Title:	Treatment of circadian rhythm disorders
Abstract:	Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Inventor(s):	Dressman; Marlene Michelle (Germantown, MD), Licamele; Louis William (Potomac, MD), Polymeropoulos; Mihael H. (Potomac, MD)
Assignee:	VANDA PHARMACEUTICALS INC. (Washington, DC)
Application Number:	15/822,162
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,449,176
Patent Claims:	1. A method of treating a disorder associated with a desynchronous cortisol circadian rhythm in an individual having a desynchronous cortisol circadian rhythm, said method comprising internally administering to the individual an effective amount of tasimelteon, wherein the disorder associated with a desynchronous cortisol circadian rhythm is selected from a group consisting of: obesity, depression, and neurological impairment. 2. The method of claim 1, wherein the individual is light perception impaired (LPI). 3. The method of claim 1, wherein the individual is totally blind. 4. The method of claim 1, wherein the individual suffers from Non-24-Hour Sleep-Wake Disorder. 5. The method of claim 1, wherein the effective amount is an amount sufficient to entrain the individual's cortisol circadian rhythm to a natural day/night cycle comprising a 24-hour sleep-wake cycle in which the individual awakens at or near a target wake time following a daily sleep period of approximately seven to nine hours. 6. The method of claim 1, wherein the tasimelteon or active metabolite thereof is administered 0.5 hour to 1.5 hours before a target bedtime. 7. The method of claim 1, wherein the administering includes administering between about 10 mg and about 100 mg of tasimelteon. 8. The method of claim 1, wherein the administering includes administering between about 20 mg and about 50 mg of tasimelteon. 9. The method of claim 1, wherein the administering includes administering about 20 mg of tasimelteon.